Abstract
BackgroundProstate cancer (Pca) remains one of the leading adult malignancies. PTEN (Phosphatase and Tensin Homolog) mutant is the top common mutated genes in prostate cancer, which makes it a promising biomarker in future individualized treatment.MethodsWe obtained gene expression data of prostate cancer from TCGA (The Cancer Genome Atlas) database for analysis. We analyzed the DEGs (differentially expressed genes), and used online tools or software to analyze Gene ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene set enrichment analysis (GSEA), Search Tool for the Retrieval of Interacting Genes/Proteins, and Molecular Complex Detection.ResultsLatest TCGA data showed PTEN mutation in about 22% patients. 1736 DEGs in total were identified. Results of gene functional enrichment analyses showed that muscle contraction, negative regulation of growth and multiple metabolic progression were significantly enriched. GNG13, ACTN2, POTEE, ACTA1, MYH6, MYH3, MYH7, MYL1, TNNC1 and TNNC2 were the top ten hub genes. Patients with PTEN mutation showed relatively decreased mRNA expression level of PTEN. Survival analysis indicated the risk of disease recurrence in patients with PTEN mutation.ConclusionsOur findings suggested that PTEN mutation in prostate cancer may induce changes in a variety of genes and pathways and affect disease progression, suggesting the significance of PTEN mutation in individualized treatment of prostate cancer.
Highlights
Prostate cancer (Pca) remains one of the leading adult malignancies
Gene set enrichment analysis (GSEA) To further explore the function of Phosphatase and Tensin Homolog (PTEN) mutation in disease progression, we analyzed the a variety of biological functional gene sets by the GSEA
We analyzed the gene expression data of prostate cancer obtained from The Cancer Genome Atlas (TCGA) to uncover the critical pathways and top hub genes associated with PTEN mutation
Summary
Prostate cancer (Pca) remains one of the leading adult malignancies. PTEN (Phosphatase and Tensin Homolog) mutant is the top common mutated genes in prostate cancer, which makes it a promising biomarker in future individualized treatment. Prostate cancer is one of the common malignant tumors in urology and is the leading cause of cancer-related mortality in men in developed countries. Previous studies have focused on signaling pathways, critical oncogenes and related cellular processes that promote disease progression, but the underlying molecular biologic mechanisms are still not clear. Gene mutations have been shown to be critical in disease program. The combined results of several studies have confirmed that PTEN is the top common mutated genes in PCa, indicating its potential clinical significance. PTEN regulates cell proliferation and survival mainly by regulating PI3K-
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
